Date: 2017-10-02
Type of
information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the 15th Annual Discovery on Target Conference
Company: OSE Immunotherapeutics (France)
Product: Effi-DEM
Action
mechanism:
- immune checkpoint inhibitor. Effi-DEM is specifically targeting the SIRP- ? receptor on the strategic SIRP-?/CD47 pathway. SIRP-? is a receptor strongly expressed by Myeloid Derived Suppressor Cells (MDSC) and Tumor Associated Macrophages (TAM) and its ligand is CD47. Suppressor immune cells MDSC and TAM play a key role in tumor growth of inflammatory cancers.
Disease:
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
- • On October 2, 2017, OSE Immunotherapeutics presented new ex vivo and preclinical data on its first-in-class checkpoint inhibitor OSE-172 targeting selectively SIRP-alpha, a target expressed on myeloid suppressive cells. The data were presented at the 15th Annual Discovery on Target Conference. Key results from the studies indicated that OSE-172 significantly:
- Reversed in vivo tumor immuno-suppressive microenvironment and decreased tumor growth in a
Triple Negative Breast Cancer (TNBC) model;
- – Inhibited metastasis spread in a TNBC model;
- – Synergized survival when combined with PD-1/ PD-L1 blockade in a HepatoCellular Carcinoma (HCC) model, reinforcing the rationale for combination treatment;
- – Induced potent memory anti-tumor immune responses when combined;
- – Reduced immunosuppressive myeloid cell function from human ovarian cancer ascites in an ex vivo
model; and
- – Bound selectively to SIRP-alpha but did not bind to SIRP-gamma, a human costimulatory receptor required for human T-cell responses.
“Myeloid suppressive cells are involved in the tumor microenvironment of various tumors impeding
T-cytotoxic cells from being effective against tumor cells. Myeloid suppressive cells play a role in tumor
growth, metastasis process and immune escape mechanisms”, said Bernard Vanhove, COO and Head of R&D
and International Scientific Collaborations at OSE Immunotherapeutics. “We are very encouraged by the
new OSE-172 human ex vivo and preclinical data, which support the development of this anti-SIRP-alpha
antibody in monotherapy and in combination with PD-1/PD-L1 checkpoint inhibitors.” OSE Immunotherapeutics now looks forward to beginning clinical trials in oncology by the end of 2018.
- • On October 4, 2016, OSE Immunotherapeutics announced that the company will present in an oral session preclinical studies results for Effi-DEM, a new generation checkpoint inhibitor targeting Myeloid Derived Suppressor Cells (MDSC) and Tumor Associated Macrophages (TAM), at the ICI (Immune Checkpoint Inhibitors) conference (Munich, November 16th to 18th, 2016). Bernard Vanhove, Chief Operating Officer of OSE Immunotherapeutics, in charge of R&D and International scientific collaborations, will present and comment all of the data from its preclinical studies conducted with Effi-DEM both in vivo and in vitro and in various cancer models. Effi-DEM has shown to be effective in various aggressive cancer models with encouraging preclinical results, both in monotherapy and in therapeutic combinations with anti-PD-L1 (checkpoint inhibitors) and anti-CD137 (4-1BB), activators of the T-cell response. Significant efficacy and survival increase data were demonstrated in hepatocarcinoma, melanoma and triple negative breast cancer models. The presentation is entitled: Selective Targeting of The SIRP-? Immune Checkpoint To Dampen Suppression By Myeloïd-Derived Suppressor Cells And Control Polarization Of Human Macrophages. These preclinical data will also be presented in an abstract at the Annual World Gene Convention-2016 (WGC-2016), which will be held during November 3-5, 2016 in Shanghai, China.
Is
general: Yes
